NCT07078591View on ClinicalTrials.gov

Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML

PHASE2RecruitingINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

June 20, 2025

Primary Completion Date

June 30, 2030

Study Completion Date

June 30, 2031

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

Venetoclax

Given PO

DRUG

Azacitidine (AZA)

Given SC

DRUG

Daunorubicin

Given IV

DRUG

Idarubicin（IDA）

Given IV

DRUG

Cytarabine (Ara-C)

Given IV

BIOLOGICAL

GPBMC infusion

HLA-mismatched donor GPBMC infusion

Trial Locations (1)

100071

RECRUITING

Department of Hematology, the Fifth Medical Center of Chinese PLA General Hospital, Beijing

All Listed Sponsors

lead

Beijing 302 Hospital

OTHER